ストックスクリーナーアプリを入手
15.60
1.27%
-0.20
アフターアワーズ：
15.96
0.36
+2.31%
前日終値:
$15.80
開ける：
$16.04
24時間の取引高:
30,667
Relative Volume:
0.06
時価総額：
$99.74M
収益：
-
当期純損益:
$-31.48M
株価収益率:
-15.00
EPS:
-1.04
ネットキャッシュフロー:
$-28.71M
1週間 パフォーマンス:
-12.26%
1か月 パフォーマンス:
-20.65%
6か月 パフォーマンス:
+7.59%
1年 パフォーマンス:
-15.97%
1日の値動き範囲:
$15.57
$16.50
1週間の範囲:
$13.82
$19.30
52週間の値動き範囲:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
名前
Forte Biosciences Inc
セクター
電話
(310) 618-6994
住所
3060 PEGASUS PARK DRIVE, DALLAS, CA
FBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
15.60 | 99.74M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-08 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | アップグレード | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | ダウングレード | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | ダウングレード | Truist | Buy → Hold |
| 2021-05-14 | 開始されました | B. Riley Securities | Buy |
| 2021-03-26 | 開始されました | Citigroup | Buy |
| 2020-08-28 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | 開始されました | Truist | Buy |
すべてを表示
Forte Biosciences Inc (FBRX) 最新ニュース
(FBRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX) - Defense World
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
(FBRX) Technical Data - Stock Traders Daily
Investors Purchase Large Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO) - Defense World
Investors Buy High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
(FBRX) Long Term Investment Analysis - Stock Traders Daily
Why Forte Biosciences (FBRX) Stock Is Trading Lower - Benzinga
CBD Life Sciences Inc. (OTCMKTS:CBDL) Short Interest Up 8,233.3% in November - Defense World
Traders Buy Large Volume of Call Options on Quantum-Si (NASDAQ:QSI) - Defense World
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors - The Manila Times
Trading (FBRX) With Integrated Risk Controls - Stock Traders Daily
FBRX Stock Soars to 52-Week High, Reaching $24.46 By Investing.com - Investing.com Nigeria
FBRX Stock Soars to 52-Week High, Reaching $24.46 - Investing.com
Forte Biosciences’ $53 Million Equity Financing - Global Legal Chronicle
Biopharma Takes on Deadly Brain Cancer After Decades of Failure - BioSpace
(FBRX) Trading Report - Stock Traders Daily
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going - MSN
FBRX Stock Soars to 52-Week High, Reaching $21.47 - Investing.com India
FBRX Stock Soars to 52-Week High, Reaching $21.47 By Investing.com - Investing.com UK
Forte Biosciences Sets R&D Day to Showcase FB102 Autoimmune Treatment Pipeline | FBRX Stock News - StockTitan
Forte Biosciences CFO acquires $124,997 in company stock By Investing.com - Investing.com Canada
Forte Biosciences CFO acquires $124,997 in company stock - Investing.com
More than $50M raised by publicly traded drug developer - The Business Journals
Dallas' Forte Biosciences Announces $53M Private Placement From Leading Healthcare Investors - dallasinnovates.com
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild - MSN
EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com
Cidara’s $100M PIPE; Pyxis Oncology’s stock falls on Phase 1 data - Endpoints News
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Forte Biosciences secures $53 million in funding By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
5 Stocks Retail Investors Are Most Bullish On At Mid-Day - MSN
Forte Biosciences Secures $53M for FB102 Advancements - TipRanks
Terns Pharmaceuticals (TERN) Stock Drops Over 5% Amidst Mixed In - GuruFocus.com
Forte Biosciences Shares Are Soaring Today: What's Going On? - Benzinga
Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results - Benzinga
Forte Biosciences secures $53 million in funding - Investing.com India
Forte Biosciences More Than Doubles on $53M Private Placement - MarketWatch
Stock Market News: Forte Biosciences +151.47%, Exicure +99.48% among top gainers during mid day trading - Business Upturn
Stock Market News: Ethan Allen Interiors down by 90.10% while Exicure gains 99.48% during mid day trading - Business Upturn
Nasdaq Tumbles Over 100 Points; TJX Earnings Top Views - Benzinga
Stock Market Today: Forte Biosciences up by 54.60% while Red Cat Holdings gains 35% in early trading - Business Upturn
Stock Market Today: Ethan Allen Interiors falls by nearly 90% while Forte Biosciences surges by 64.89% in early trading - Business Upturn
US Stocks Mostly Lower; Target Posts Downbeat Earnings - Benzinga
Thrive Tribe Technologies Affirms ASX Compliance Amid Stock Query - MSN
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications - The Bakersfield Californian
Forte Biosciences Secures $53M Private Placement for Autoimmune Drug Development | FBRX Stock News - StockTitan
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
IBD Rating Upgrades: Chesapeake Utilities Flashes Improved Relative Price Strength - MSN
Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight - Lelezard
Forte Biosciences Inc (FBRX) 財務データ
収益
当期純利益
現金流量
EPS
Forte Biosciences Inc (FBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Nov 21 '24 |
Buy |
5.55 |
22,514 |
124,998 |
30,776 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
203,849 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,910,424 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
197,819 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,881,627 |
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):